Browse Category

NASDAQ:IBIO 21 October 2025 - 13 March 2026

ImmunityBio Stock Jumps After NK-Cell Manufacturing Update Puts Anktiva Expansion Back in Focus
iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

iBio (IBIO) Stock Jumps on Obesity Drug Momentum: All the Latest News, Analyst Targets and 2026–2027 Outlook (December 9, 2025)

As of December 9, 2025, iBio, Inc. has turned into one of the louder tickers in the obesity‑drug corner of biotech. After closing Monday, December 8 at $1.67, up 39% on the day, IBIO is trading higher again in pre‑market action on Tuesday, with quotes between $1.76 and $1.81, pushing its market value to roughly $37–38 million.Benzinga
9 December 2025
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

As of midday October 21, 2025, iBio’s stock trades around $0.89 per sharemarketbeat.com. The price has been volatile in recent days. Last week, shares jumped over 20% in pre-market trading on October 17 after Leerink Partners issued a bullish initiation, although the stock later settled near $0.85 by that day’s closemarketbeat.com. Even with these upticks, iBio’s stock remains well below its levels earlier this year – it began 2025 at ~$2.45 and has declined about 63% year-to-datemarketbeat.com. This underperformance comes amid broader small-cap biotech volatility; by comparison, the biotech sector ETF is up roughly 20% in 2025finance.yahoo.com. iBio’s modest market capitalization and thin trading volume reflect its micro-cap statusmarketbeat.comreuters.com, which can magnify price swings on news.
21 October 2025
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

Walt Disney

NYSE: DIS 94 / 100
#2 BUY

AerCap

NYSE: AER 92 / 100
#3 TACTICAL BUY

Advanced Micro Devices

NASDAQ: AMD 90 / 100
#4 BUY ON WEAKNESS

Arista Networks

NYSE: ANET 88 / 100
#5 SPECULATIVE BUY

Albemarle

NYSE: ALB 85 / 100
View full portfolio
Editorial model selection. Not personalised advice.